Sangamo Therapeutics (SGMO) Getting Somewhat Favorable News Coverage, Study Shows

Share on StockTwits

News coverage about Sangamo Therapeutics (NASDAQ:SGMO) has been trending somewhat positive on Sunday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.2486793418607 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Sangamo Therapeutics opened at $16.50 on Friday, MarketBeat.com reports. Sangamo Therapeutics has a twelve month low of $8.00 and a twelve month high of $27.50. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.78 and a current ratio of 4.78. The company has a market capitalization of $1.64 billion, a PE ratio of -23.57 and a beta of 2.89.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.29 by ($0.52). Sangamo Therapeutics had a negative net margin of 126.96% and a negative return on equity of 30.96%. The company had revenue of $12.60 million during the quarter, compared to the consensus estimate of $53.09 million. During the same quarter in the prior year, the business earned ($0.23) EPS. The firm’s revenue for the quarter was up 270.6% compared to the same quarter last year. equities research analysts anticipate that Sangamo Therapeutics will post -0.65 EPS for the current fiscal year.

Several research analysts have issued reports on SGMO shares. BidaskClub lowered Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 17th. Zacks Investment Research lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 10th. Bank of America started coverage on Sangamo Therapeutics in a report on Wednesday. They issued a “buy” rating and a $24.00 price target on the stock. Barclays reiterated a “buy” rating and issued a $30.00 price target on shares of Sangamo Therapeutics in a report on Sunday, February 25th. Finally, Wedbush reiterated a “hold” rating and issued a $8.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Sangamo Therapeutics presently has an average rating of “Buy” and a consensus target price of $22.00.

In other news, VP Curt A. Herberts III sold 8,163 shares of the firm’s stock in a transaction that occurred on Friday, April 13th. The stock was sold at an average price of $20.00, for a total value of $163,260.00. Following the transaction, the vice president now owns 22,788 shares in the company, valued at $455,760. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven J. Mento sold 7,215 shares of Sangamo Therapeutics stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $18.40, for a total value of $132,756.00. The disclosure for this sale can be found here. Insiders sold 47,656 shares of company stock worth $844,303 in the last 90 days. Corporate insiders own 1.20% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.